Close

More on GILD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+13.9% Growth)
- Ratings (5.7 Score)
- Holders
- Dividends (4.6% Yield)
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (4/25/24)
- M&A (6/30/20 *Est)
- M&A (12/31/20 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

GILD Balance Sheet

Click line-items for a historical chart and %
Assets
Cash and cash equivalents 9.81B
Short-term marketable securities 2.46B
Accounts receivable, net 5.08B
Inventories 1.9B
Deferred tax assets 762M
Prepaid taxes
Prepaid expenses
Other current assets
Total current assets 21.43B
Property, plant and equipment, net 2.71B
Noncurrent portion of prepaid royalties 439M
Noncurrent deferred tax assets 481M
Long-term marketable securities 19.35B
Intangible assets
Other noncurrent assets 1.65B
Total assets 56.61B
Liabilities and Stockholders' Equity
Accounts payable 1.05B
Accrued government rebates
Accrued compensation and employee benefits
Income taxes payable
Other accrued liabilities 3.48B
Deferred revenues 361M
Current portion of long-term debt and other obligations, net 700M
Total current liabilities 11.07B
Long-term deferred revenues
Long term debt, net
Long-term income taxes payable 1.62B
Other long-term obligations 184M
Commitments and contingencies (Note 10) 0
Stockholders' equity:
Preferred stock, par value $0.001 per share; 5,000 shares authorized; none outstanding 0
Common stock, par value $0.001 per share; 2,800,000 shares authorized; 776,405 and 801,998 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 1M
Additional paid-in capital 321M
Accumulated other comprehensive income (loss) -108M
Retained earnings 16.65B
Total Gilead stockholders' equity 16.87B
Noncontrolling interest 492M
Total stockholders' equity 17.36B
Total liabilities and stockholders' equity 56.61B